Sage Journals: Discover world-class research

Retricted access

Research article

First published 2009-8

Developing a Legislative Pathway for Biosimilars in the United States

Henry A. Waxman

Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector

Retricted access

Research article

First published 2005-1

The EU Regulatory Environment for ‘Biosimilars’: Today's Picture and Future Prospects

Nicolas Rossignol

Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector

Retricted access

Research article

First published 2023-04

A 2023 Review of Legislation Aimed at Increasing Generic and Biosimilar Competition

Christopher M. Holman

Biotechnology Law Report

Retricted access

Review article

First published 2016-8

Biosimilars: Hope and concern

Christos E Emmanouilides, Maria I Karampola, Maria Beredima

Journal of Oncology Pharmacy Practice

Retricted access

Research article

First published 2019-3

The trend in patent infringement litigation against generic drugs or biosimilars in Japan

Sachiko Masuda

Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector

Free access

Research article

First published 2016-9

In the Biosimilar Marketplace Will There Be 50 Ways to Leave Your Insulin?

Alan W. Carter

Journal of Diabetes Science and Technology

Retricted access

Research article

First published 2020-1

Perception of hematologists and oncologists about the biosimilars: A prospective Tunisian study based on a survey

Selma Hadoussa, Mehdi Bouhlel, Mohamed A Soussi [...]

Journal of Oncology Pharmacy Practice

Retricted access

Research article

First published 2013-9

What's in a name?—The identification of biologic products

Ralph G Neas, David R Gaugh

Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector

Retricted access

Research article

First published 2012-3

Complex Drugs and Biologics: Scientific and Regulatory Challenges for Follow-on Products

J. Michael Nicholas

Therapeutic Innovation & Regulatory Science

Retricted access

Other

First published 2011-3

Requirements for Biosimilars and Interchangeable Biological Drugs in the United States—in Plain Language

Suzanne M. Sensabaugh

Therapeutic Innovation & Regulatory Science

Search results